Specialty Business Services
Compare Stocks
2 / 10Stock Comparison
MMS vs CNXC
Revenue, margins, valuation, and 5-year total return — side by side.
Information Technology Services
MMS vs CNXC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Specialty Business Services | Information Technology Services |
| Market Cap | $3.49B | $1.67B |
| Revenue (TTM) | $5.37B | $9.83B |
| Net Income (TTM) | $372M | $-1.28B |
| Gross Margin | 23.8% | 33.3% |
| Operating Margin | 10.8% | 6.2% |
| Forward P/E | 7.5x | 2.0x |
| Total Debt | $1.44B | $4.64B |
| Cash & Equiv. | $260M | $327M |
MMS vs CNXC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 20 | May 26 | Return |
|---|---|---|---|
| Maximus, Inc. (MMS) | 100 | 89.1 | -10.9% |
| Concentrix Corporat… (CNXC) | 100 | 29.6 | -70.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MMS vs CNXC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
MMS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 2.4%, EPS growth 10.4%, 3Y rev CAGR 5.5%
- 35.2% 10Y total return vs CNXC's -63.2%
- Lower volatility, beta 0.72, Low D/E 86.3%, current ratio 1.64x
CNXC is the clearest fit if your priority is income & stability.
- Dividend streak 5 yrs, beta 1.38, yield 6.0%
- Lower P/E (2.0x vs 7.5x)
- 6.0% yield, 5-year raise streak, vs MMS's 1.9%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 2.4% revenue growth vs CNXC's 2.2% | |
| Value | Lower P/E (2.0x vs 7.5x) | |
| Quality / Margins | 6.9% margin vs CNXC's -13.0% | |
| Stability / Safety | Beta 0.72 vs CNXC's 1.38, lower leverage | |
| Dividends | 6.0% yield, 5-year raise streak, vs MMS's 1.9% | |
| Momentum (1Y) | -1.9% vs CNXC's -50.0% | |
| Efficiency (ROA) | 8.8% ROA vs CNXC's -10.8%, ROIC 15.1% vs 5.6% |
MMS vs CNXC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
MMS vs CNXC — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
Evenly matched — MMS and CNXC each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
CNXC is the larger business by revenue, generating $9.8B annually — 1.8x MMS's $5.4B. MMS is the more profitable business, keeping 6.9% of every revenue dollar as net income compared to CNXC's -13.0%. On growth, CNXC holds the edge at +4.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $5.4B | $9.8B |
| EBITDAEarnings before interest/tax | $715M | $773M |
| Net IncomeAfter-tax profit | $372M | -$1.3B |
| Free Cash FlowCash after capex | $218M | $572M |
| Gross MarginGross profit ÷ Revenue | +23.8% | +33.3% |
| Operating MarginEBIT ÷ Revenue | +10.8% | +6.2% |
| Net MarginNet income ÷ Revenue | +6.9% | -13.0% |
| FCF MarginFCF ÷ Revenue | +4.1% | +5.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -4.1% | +4.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +146.4% | -14.9% |
Valuation Metrics
CNXC leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, CNXC's 4.7x EV/EBITDA is more attractive than MMS's 6.5x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $3.5B | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $4.7B | $6.0B |
| Trailing P/EPrice ÷ TTM EPS | 11.61x | -1.17x |
| Forward P/EPrice ÷ next-FY EPS est. | 7.51x | 2.03x |
| PEG RatioP/E ÷ EPS growth rate | 1.14x | — |
| EV / EBITDAEnterprise value multiple | 6.47x | 4.75x |
| Price / SalesMarket cap ÷ Revenue | 0.64x | 0.17x |
| Price / BookPrice ÷ Book value/share | 2.21x | 0.54x |
| Price / FCFMarket cap ÷ FCF | 9.53x | 2.91x |
Profitability & Efficiency
MMS leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
MMS delivers a 21.6% return on equity — every $100 of shareholder capital generates $22 in annual profit, vs $-33 for CNXC. MMS carries lower financial leverage with a 0.86x debt-to-equity ratio, signaling a more conservative balance sheet compared to CNXC's 1.69x. On the Piotroski fundamental quality scale (0–9), MMS scores 8/9 vs CNXC's 5/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +21.6% | -33.2% |
| ROA (TTM)Return on assets | +8.8% | -10.8% |
| ROICReturn on invested capital | +15.1% | +5.6% |
| ROCEReturn on capital employed | +17.4% | +6.6% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 5 |
| Debt / EquityFinancial leverage | 0.86x | 1.69x |
| Net DebtTotal debt minus cash | $1.2B | $4.3B |
| Cash & Equiv.Liquid assets | $260M | $327M |
| Total DebtShort + long-term debt | $1.4B | $4.6B |
| Interest CoverageEBIT ÷ Interest expense | 6.97x | -3.07x |
Total Returns (Dividends Reinvested)
MMS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MMS five years ago would be worth $7,540 today (with dividends reinvested), compared to $1,899 for CNXC. Over the past 12 months, MMS leads with a -1.9% total return vs CNXC's -50.0%. The 3-year compound annual growth rate (CAGR) favors MMS at -5.3% vs CNXC's -31.4% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -25.7% | -40.7% |
| 1-Year ReturnPast 12 months | -1.9% | -50.0% |
| 3-Year ReturnCumulative with dividends | -15.0% | -67.8% |
| 5-Year ReturnCumulative with dividends | -24.6% | -81.0% |
| 10-Year ReturnCumulative with dividends | +35.2% | -63.2% |
| CAGR (3Y)Annualised 3-year return | -5.3% | -31.4% |
Risk & Volatility
MMS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MMS is the less volatile stock with a 0.72 beta — it tends to amplify market swings less than CNXC's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MMS currently trades 63.9% from its 52-week high vs CNXC's 38.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.72x | 1.38x |
| 52-Week HighHighest price in past year | $100.00 | $62.14 |
| 52-Week LowLowest price in past year | $60.75 | $22.85 |
| % of 52W HighCurrent price vs 52-week peak | +63.9% | +38.2% |
| RSI (14)Momentum oscillator 0–100 | 40.2 | 36.5 |
| Avg Volume (50D)Average daily shares traded | 664K | 1.6M |
Analyst Outlook
CNXC leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Wall Street rates MMS as "Buy" and CNXC as "Buy". Consensus price targets imply 119.2% upside for CNXC (target: $52) vs 72.0% for MMS (target: $110). For income investors, CNXC offers the higher dividend yield at 6.00% vs MMS's 1.85%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $110.00 | $52.00 |
| # AnalystsCovering analysts | 16 | 9 |
| Dividend YieldAnnual dividend ÷ price | +1.9% | +6.0% |
| Dividend StreakConsecutive years of raises | 2 | 5 |
| Dividend / ShareAnnual DPS | $1.19 | $1.42 |
| Buyback YieldShare repurchases ÷ mkt cap | +12.8% | +11.3% |
MMS leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). CNXC leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.
MMS vs CNXC: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is MMS or CNXC a better buy right now?
For growth investors, Maximus, Inc.
(MMS) is the stronger pick with 2. 4% revenue growth year-over-year, versus 2. 2% for Concentrix Corporation (CNXC). Maximus, Inc. (MMS) offers the better valuation at 11. 6x trailing P/E (7. 5x forward), making it the more compelling value choice. Analysts rate Maximus, Inc. (MMS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — MMS or CNXC?
On forward P/E, Concentrix Corporation is actually cheaper at 2.
0x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — MMS or CNXC?
Over the past 5 years, Maximus, Inc.
(MMS) delivered a total return of -24. 6%, compared to -81. 0% for Concentrix Corporation (CNXC). Over 10 years, the gap is even starker: MMS returned +35. 2% versus CNXC's -63. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — MMS or CNXC?
By beta (market sensitivity over 5 years), Maximus, Inc.
(MMS) is the lower-risk stock at 0. 72β versus Concentrix Corporation's 1. 38β — meaning CNXC is approximately 90% more volatile than MMS relative to the S&P 500. On balance sheet safety, Maximus, Inc. (MMS) carries a lower debt/equity ratio of 86% versus 169% for Concentrix Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — MMS or CNXC?
By revenue growth (latest reported year), Maximus, Inc.
(MMS) is pulling ahead at 2. 4% versus 2. 2% for Concentrix Corporation (CNXC). On earnings-per-share growth, the picture is similar: Maximus, Inc. grew EPS 10. 4% year-over-year, compared to -648. 8% for Concentrix Corporation. Over a 3-year CAGR, CNXC leads at 15. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — MMS or CNXC?
Maximus, Inc.
(MMS) is the more profitable company, earning 5. 9% net margin versus -13. 0% for Concentrix Corporation — meaning it keeps 5. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MMS leads at 10. 6% versus 6. 2% for CNXC. At the gross margin level — before operating expenses — CNXC leads at 35. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is MMS or CNXC more undervalued right now?
On forward earnings alone, Concentrix Corporation (CNXC) trades at 2.
0x forward P/E versus 7. 5x for Maximus, Inc. — 5. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CNXC: 119. 2% to $52. 00.
08Which pays a better dividend — MMS or CNXC?
All stocks in this comparison pay dividends.
Concentrix Corporation (CNXC) offers the highest yield at 6. 0%, versus 1. 9% for Maximus, Inc. (MMS).
09Is MMS or CNXC better for a retirement portfolio?
For long-horizon retirement investors, Maximus, Inc.
(MMS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72), 1. 9% yield). Both have compounded well over 10 years (MMS: +35. 2%, CNXC: -63. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between MMS and CNXC?
These companies operate in different sectors (MMS (Industrials) and CNXC (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: MMS is a small-cap deep-value stock; CNXC is a small-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.